RCS - Arecor Therapeutics - Arecor to present on Investor Meet Company

Arecor Therapeutics

24/04/2025 07:00

RNS Number : 9385F

Arecor Therapeutics PLC

24 April 2025

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Arecor to present on Investor Meet Company platform

 

Cambridge, UK, 24 April 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will be providing a live presentation of the Group's recently announced final results for the year ended 31 December 2024 via the Investor Meet Company platform on Thursday 1 May 2025 at 2pm BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 30 April 2025, 09:00 BST, or at any time during the live presentation.

 

To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:

https://www.investormeetcompany.com/companies/arecor-therapeutics-plc

 

Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.

 

-ENDS-

 

For more information, please contact:

 

Arecor Therapeutics plc
www.arecor.com
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
David Ellam, Chief Financial Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Broker)
Phil Davies, Sam Butcher
Tel: +44 (0) 20 7496 3000
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville
Tel: +44 (0) 20 3709 5700
Email:arecor@icrhealthcare.com


Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAUOABRVKUSUAR